In Silico Characterization of FABP5-Associated Candidate Genes in Prostate Cancer Progression
Onco · 2026-11-09 · 6 (4) · 54
DOI: 10.3390/onco6040054 ↗Abstract
Background/Objectives: Previous CRISPR-Cas9-mediated knockout experiments targeting the androgen receptor (AR) and fatty acid-binding protein 5 (FABP5) in castration-resistant prostate cancer (CRPC) cell models identified a shared transcriptomic signature comprising genes potentially involved in prostate cancer progression. The present study aimed to investigate the expression patterns, clinicopathological associations, and biological characteristics of these experimentally derived candidate genes using publicly available prostate cancer datasets, predominantly representing primary prostate adenocarcinoma. Methods: Five commonly dysregulated genes (FASN, FOSB, GRPR, PPARG, and CAV1), identified through comparative transcriptomic analyses, together with FABP5, were evaluated using multiple prostate cancer databases. Gene expression, clinicopathological associations, disease progression, genomic alterations, protein expression, and functional enrichment analyses were performed using integrated bioinformatics approaches. Correlation analyses with AR, KLK3, and VEGFA were also conducted. Results: FABP5, FASN, FOSB, and GRPR were significantly upregulated in prostate adenocarcinoma, whereas PPARG and CAV1 were significantly downregulated relative to normal prostate tissues. Several candidate genes exhibited significant associations with Gleason score, expression differences across the analyzed disease groups, and correlations with established prostate cancer biomarkers. Protein-level assessment using Human Protein Atlas data suggested increased FABP5 and FASN protein expression in high-grade prostate adenocarcinoma tissues compared with low-grade tumors, providing descriptive observations consistent with the transcriptomic findings rather than quantitative protein-level validation. Functional enrichment analyses identified significant enrichment of lipid metabolism, PPAR signaling, fatty acid biosynthesis, and hormone-responsive pathways. Conclusions: This integrative in silico study identified consistent expression alterations and clinicopathological associations involving FABP5 and five related candidate genes in prostate cancer datasets. These findings support further investigation of the FABP5-associated gene set as a potential source of biomarkers. Exploratory survival findings did not establish prognostic utility; independent prospective clinical and functional validation remains necessary.
EUVIMED